boehringer

Boehringer Ingelheim advances potential first-in-class IL-11 inhibitor to Phase II Clinical Research in Idiopathic Pulmonary Fibrosis

Not intended for US and UK audiences BI 765423 has been developed to target IL-11, a key driver of fibrosis…

2 days ago

Boehringer Ingelheim announces appointment to Board of Managing Directors

Harsha Deshmukh has been appointed a member of the Board of Managing Directors with responsibility for IT and Global Business…

2 months ago